This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Transaction (as described below) pursuant to that certain Transaction Agreement, dated October 5, 2023 (the ? Transaction Agreement?), between Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the ? Company?), and Kyowa Kirin Co.

Ltd., a Japanese joint stock company (? Kyowa Kirin?). As previously announced, on January 22, 2024, the High Court of Justice of England and Wales (the ?

Court?) sanctioned the acquisition by Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin, of the entire issued and to be issued share capital of the Company pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006 (the ? Scheme of Arrangement?, and such acquisition, the ? Transaction?) at a public hearing convened by the Court.

On January 24, 2024 (the ? Closing Date?), the Court?s order which sanctioned the Scheme of Arrangement was delivered to the Registrar of Companies in England and Wales and, as a result, the Company and Kyowa Kirin consummated the Transaction in accordance with the Transaction Agreement and the Scheme of Arrangement. In connection with the Transaction, Alicia Secor, Charles Rowland, Jim Geraghty, John Curnutte, Joanne Beck, Steven Altschuler and Marc Dunoyer each resigned from the Board of Directors of the Company (the ?

Board?) and from any and all committees of the Board on which they served and ceased to be directors of the Company at the Effective Time. On January 24, 2024, the Board appointed Takeyoshi Yamashita, Yasuo Fujii and Abdul Mullick as directors of the Company.